Patriot Coal (NYSE: PCX), Petrohawk Energy (NYSE: HK), DeVry Inc. (NYSE: DV), AngioDynamics (NASDAQ: ANGO) and Pharmaceutical Product Development (NASDAQ: PPDI) upgraded by analysts.
Canaccord Genuity upgraded AngioDynamics (ANGO) from a “Hold” rating to a “Buy” rating. They have a price target of $16.50 on the company, up from $15.00.
UBS AG (NYSE: UBS) upgraded DeVry Inc. (DV) from a “Neutral” rating to a “Buy” rating. They have a price target of $75.00 on the company, up from $55.00.
Lazard Capital upgraded Petrohawk Energy (HK) was upgraded by analysts at from a “Sell” rating to a “Neutral” rating.
BMO Capital Markets upgraded Patriot Coal (PCX) to a “Market Perform” rating.
William Blair upgraded Pharmaceutical Product Development (PPDI) from a “Market Perform” rating to an “Outperform” Rating.
Showing posts with label AngioDynamics. Show all posts
Showing posts with label AngioDynamics. Show all posts
Monday, July 18, 2011
Thursday, January 27, 2011
AngioDynamics' (NASDAQ:ANGO) NanoKnife Warning Immaterial, Says Canaccord, Buy on Weakness
Speaking to the recent warning by the FDA concerning the Nanoknife, Canaccord Genuity said they don't think it'll have much impact on AngioDynamics (NASDAQ:ANGO), and recommend buying the company on weakness.
Canaccord says, "We do not believe the recently-announced FDA warning will have any material impact on NanoKnife US clinical timelines, albeit we think there could be modest disruption to US commercial sales if hospital administrators or payors become more cautious near term. That said, we are not changing our NanoKnife estimates ($1.6M NanoKnife sales WW in FQ3E; ~3% of sales)...We would be opportunistic buyers of the stock on weakness >10% near term."
Canaccord Genuity maintains a "Hold" rating on AngioDynamics (ANGO), which closed Wednesday at $16.58, up $0.39, or 2.41 percent. Canaccord has a price target of $17 on them.
Canaccord says, "We do not believe the recently-announced FDA warning will have any material impact on NanoKnife US clinical timelines, albeit we think there could be modest disruption to US commercial sales if hospital administrators or payors become more cautious near term. That said, we are not changing our NanoKnife estimates ($1.6M NanoKnife sales WW in FQ3E; ~3% of sales)...We would be opportunistic buyers of the stock on weakness >10% near term."
Canaccord Genuity maintains a "Hold" rating on AngioDynamics (ANGO), which closed Wednesday at $16.58, up $0.39, or 2.41 percent. Canaccord has a price target of $17 on them.
Thursday, January 6, 2011
AngioDynamics (NASDAQ:ANGO) Growth in PV, Access Businesses Uncertain
While Canaccord believes AngioDynamics (NASDAQ:ANGO) has the ability to continue generating solid cash flow and earnings, they are concerned about the uncertainty connected to their PV and Access businesses.
Canaccord said, "FQ2/11 (Nov) results showed continued challenges on the top line, but earnings results beat expectations owing to solid GM improvements, OpEx control and lower tax rate. We increase our target to $17 (30x C2011 EPS) from $15, and are incrementally more optimistic about ANGO’s ability to continue to deliver solid earnings and cash flow results. However, we maintain our HOLD rating as reacceleration of growth in the PV and Access businesses remains uncertain in the wake of a reorganized sales force."
Canaccord Genuity maintains a "Hold" rating on AngioDynamics, which closed Wednesday at $16.10, gaining $0.71, or 4.61 percent. Canaccord raised their price target on them to $17.
Canaccord said, "FQ2/11 (Nov) results showed continued challenges on the top line, but earnings results beat expectations owing to solid GM improvements, OpEx control and lower tax rate. We increase our target to $17 (30x C2011 EPS) from $15, and are incrementally more optimistic about ANGO’s ability to continue to deliver solid earnings and cash flow results. However, we maintain our HOLD rating as reacceleration of growth in the PV and Access businesses remains uncertain in the wake of a reorganized sales force."
Canaccord Genuity maintains a "Hold" rating on AngioDynamics, which closed Wednesday at $16.10, gaining $0.71, or 4.61 percent. Canaccord raised their price target on them to $17.
Subscribe to:
Posts (Atom)